Search

Your search keyword '"Kullberg, Bart-Jan"' showing total 706 results
Start Over Author "Kullberg, Bart-Jan" Publication Type Academic Journals
706 results on '"Kullberg, Bart-Jan"'

1. A comprehensive genetic map of cytokine responses in Lyme borreliosis

Author

Botey-Bataller, Javier, Vrijmoeth, Hedwig D., Ursinus, Jeanine, Kullberg, Bart-Jan, van den Wijngaard, Cees C., ter Hofstede, Hadewych, Alaswad, Ahmed, Gupta, Manoj K., Roesner, Lennart M., Huehn, Jochen, Werfel, Thomas, Schulz, Thomas F., Xu, Cheng-Jian, Netea, Mihai G., Hovius, Joppe W., Joosten, Leo A. B., and Li, Yang

Published
2024
Full Text
View/download PDF

3. Efficacy and safety of rezafungin and caspofungin in candidaemia and invasive candidiasis: pooled data from two prospective randomised controlled trials

Author

Thompson, George R, III, Soriano, Alex, Honore, Patrick M, Bassetti, Matteo, Cornely, Oliver A, Kollef, Marin, Kullberg, Bart Jan, Pullman, John, Hites, Maya, Fortún, Jesús, Horcajada, Juan P, Kotanidou, Anastasia, Das, Anita F, Sandison, Taylor, Aram, Jalal A, Vazquez, Jose A, and Pappas, Peter G

Published
2024
Full Text
View/download PDF

5. Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium

Author

Donnelly, J Peter, Chen, Sharon C, Kauffman, Carol A, Steinbach, William J, Baddley, John W, Verweij, Paul E, Clancy, Cornelius J, Wingard, John R, Lockhart, Shawn R, Groll, Andreas H, Sorrell, Tania C, Bassetti, Matteo, Akan, Hamdi, Alexander, Barbara D, Andes, David, Azoulay, Elie, Bialek, Ralf, Bradsher, Robert W, Bretagne, Stephane, Calandra, Thierry, Caliendo, Angela M, Castagnola, Elio, Cruciani, Mario, Cuenca-Estrella, Manuel, Decker, Catherine F, Desai, Sujal R, Fisher, Brian, Harrison, Thomas, Heussel, Claus Peter, Jensen, Henrik E, Kibbler, Christopher C, Kontoyiannis, Dimitrios P, Kullberg, Bart-Jan, Lagrou, Katrien, Lamoth, Frédéric, Lehrnbecher, Thomas, Loeffler, Jurgen, Lortholary, Olivier, Maertens, Johan, Marchetti, Oscar, Marr, Kieren A, Masur, Henry, Meis, Jacques F, Morrisey, C Orla, Nucci, Marcio, Ostrosky-Zeichner, Luis, Pagano, Livio, Patterson, Thomas F, Perfect, John R, Racil, Zdenek, Roilides, Emmanuel, Ruhnke, Marcus, Prokop, Cornelia Schaefer, Shoham, Shmuel, Slavin, Monica A, Stevens, David A, Thompson, George R, Vazquez, Jose A, Viscoli, Claudio, Walsh, Thomas J, Warris, Adilia, Wheat, L Joseph, White, P Lewis, Zaoutis, Theoklis E, and Pappas, Peter G

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Cancer, Prevention, Clinical Research, Good Health and Well Being, Antifungal Agents, Consensus, Humans, Immunocompromised Host, Invasive Fungal Infections, Mycoses, Neoplasms, consensus, definitions, invasive fungal diseases, diagnosis, research, Biological Sciences, Medical and Health Sciences, Microbiology, Clinical sciences
Abstract

BackgroundInvasive fungal diseases (IFDs) remain important causes of morbidity and mortality. The consensus definitions of the Infectious Diseases Group of the European Organization for Research and Treatment of Cancer and the Mycoses Study Group have been of immense value to researchers who conduct clinical trials of antifungals, assess diagnostic tests, and undertake epidemiologic studies. However, their utility has not extended beyond patients with cancer or recipients of stem cell or solid organ transplants. With newer diagnostic techniques available, it was clear that an update of these definitions was essential.MethodsTo achieve this, 10 working groups looked closely at imaging, laboratory diagnosis, and special populations at risk of IFD. A final version of the manuscript was agreed upon after the groups' findings were presented at a scientific symposium and after a 3-month period for public comment. There were several rounds of discussion before a final version of the manuscript was approved.ResultsThere is no change in the classifications of "proven," "probable," and "possible" IFD, although the definition of "probable" has been expanded and the scope of the category "possible" has been diminished. The category of proven IFD can apply to any patient, regardless of whether the patient is immunocompromised. The probable and possible categories are proposed for immunocompromised patients only, except for endemic mycoses.ConclusionsThese updated definitions of IFDs should prove applicable in clinical, diagnostic, and epidemiologic research of a broader range of patients at high-risk.

Published
2020

6. Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial

Author

Akova, Murat, AlAgha, Rawan, Alangaden, George, Albrecht, Svenja J, Alexander, Barbara, Al-Obaidi, Mohanad, Ambasch, German, Armestar Rodriguez, Fernando, Azap, Alpay, Baffoe-Bonnie, Anthony, Belkhir, Leila, Ben-Ami, Ronen, Boutoille, David, Cascio, Antonio, Chai, Louis YA, Chaiwarith, Romanee, Chayakulkeeree, Methee, Chen, Sharon, Chen, Yee-Chun, Chen, Yen-Hsu, Choi, Jun Yong, Choi, Young Hwa, Chotiprasitsakul, Darunee, Chung, Jin Won, Danion, François, Denis, Blandine, Diaz Santos, Emilio, Dictar, Miguel O, Diltoer, Marc, Dupont, Herve, Feng, Sizhou, Ferre Colomer, Maria Angeles, Ferrer, Ricard, Forel, Jean-Marie Fernand Roger, Fortún-Abete, Jesús, Garcia-Diaz, Julia, Girardis, Massimo, He, Fang, Hites, Maya, Ho, Mao-Wang, Honore, Patrick, Horcajada Gallego, Juan Pablo, Huang, Haihui, Huang, Po-Yen, Huang, Yong, Hussein, Osamah, Intalapaporn, Poj, Jaruratanasirikul, Sutep, Jauregui-Peredo, Luis, Johnson, Misty, Jung, Dong Sik, Jutivorakool, Kamonwan, Kern, Winfried V, Kett, Daniel H, Khawcharoenporn, Thana, Kim, Young Keun, Koehler, Philipp, Kotanidou, Anastasia, Lachiewicz, Anne, Lin, Qinhan, Lopez Cortes, Luis Eduardo, Luo, Hong, Luzzati, Roberto, Maor, Yasmin, McCarty, Todd, Merelli, Maria, Merino Amador, Paloma, Midturi, John, Migliorino, Guglielmo Marco, Mira, Jean-Paul, Mootsikapun, Piroon, Morrissey, Orla, Munoz Garcia de Paredes, Patricia, Mussini, Cristina, Mylonakis, Eleftherios, Nseir, Saadalla, Nseir, William, Odabasi, Zekaver, Papastamopoulos, Vasileios, Paterson, David, Patterson, Thomas F, Peck, Kyong Ran, Peng, Zhiyong, Permpalung, Nitipong, Plantefeve, Gaetan J, Poromanski, Ivan G, Powell, Debra, Psichogiou, Mina, Puah, Ser Hon, Pullman, John, Rahav, Galia, Martinez, Antonio Ramos, Ramos Ramos, Juan Carlos, Raz-Pasteur, Ayelet, Restrepo Castro, Carlos A, Riera, Fernando, Roblot, France, Rodriguez Alvarez, Regino Jose, Rogers, Benjamin, Roilides, Emmanuel, Sanchez Vallejo, Gregorio, Sganga, Gabriele, Sipsas, Nikolaos, Slavin, Monica, Soriano, Alex, Spec, Andrej, Strahilevitz, Jacob, Tancheva, Dora M, Tao, Zhen, Teschner, Daniel, Thompson, George R, Van Wijngaerden, Eric, Vazquez, Jose, Vergidis, Paschalis, Viale, Pierluigi, Wang, Fu-Der, Wang, Shifu, Weber, Gabriel, Weng, Jianyu, Xu, Jinfu, Yao, Li, Yavuz, Serap, Yilmaz, Mesut, Young, Jo-Anne, Zarate, Abel H, Zeng, Jun, Zhang, Yong, Thompson, George R, III, Cornely, Oliver A, Kullberg, Bart Jan, Kollef, Marin, Honore, Patrick M, Bassetti, Matteo, Poromanski, Ivan, Dignani, Cecilia, Das, Anita F, Sandison, Taylor, and Pappas, Peter G

Published
2023
Full Text
View/download PDF

7. Risk Factors for Intra-Abdominal Candidiasis in Intensive Care Units: Results from EUCANDICU Study

Author

Bassetti, Matteo, Vena, Antonio, Giacobbe, Daniele R., Trucchi, Cecilia, Ansaldi, Filippo, Antonelli, Massimo, Adamkova, Vaclava, Alicino, Cristiano, Almyroudi, Maria-Panagiota, Atchade, Enora, Azzini, Anna M., Brugnaro, Pierluigi, Carannante, Novella, Peghin, Maddalena, Berruti, Marco, Carnelutti, Alessia, Castaldo, Nadia, Corcione, Silvia, Cortegiani, Andrea, Dimopoulos, George, Dubler, Simon, García-Garmendia, José L., Girardis, Massimo, Cornely, Oliver A., Ianniruberto, Stefano, Kullberg, Bart Jan, Lagrou, Katrien, Lebihan, Clement, Luzzati, Roberto, Malbrain, Manu, Merelli, Maria, Marques, Ana J., Martin-Loeches, Ignacio, Mesini, Alessio, Paiva, José-Artur, Raineri, Santi Maurizio, Rautemaa-Richardson, Riina, Schouten, Jeroen, Spapen, Herbert, Tasioudis, Polychronis, Timsit, Jean-François, Tisa, Valentino, Tumbarello, Mario, Van den Berg, Charlotte H. S. B., Veber, Benoit, Venditti, Mario, Voiriot, Guillaume, Wauters, Joost, Zappella, Nathalie, and Montravers, Philippe

Published
2022
Full Text
View/download PDF

13. Towards personalized medicine: a scoping review of immunotherapy in sepsis.

Author

Slim, Marleen A., van Mourik, Niels, Bakkerus, Lieke, Fuller, Katherine, Acharya, Lydia, Giannidis, Tatiana, Dionne, Joanna C., Oczkowski, Simon J. W., Netea, Mihai G., Pickkers, Peter, Giamarellos-Bourboulis, Evangelos J., Müller, Marcella C. A., van der Poll, Tom, Wiersinga, W. Joost, Kullberg, Bart-Jan, Nooijer, Aline, Veerdonk, Frank, Oever, Jaap, Hoogerwerf, Jacobien, and Hulscher, Marlies

Abstract

Despite significant progress in our understanding of the pathophysiology of sepsis and extensive clinical research, there are few proven therapies addressing the underlying immune dysregulation of this life-threatening condition. The aim of this scoping review is to describe the literature evaluating immunotherapy in adult patients with sepsis, emphasizing on methods providing a "personalized immunotherapy" approach, which was defined as the classification of patients into a distinct subgroup or subphenotype, in which a patient's immune profile is used to guide treatment. Subgroups are subsets of sepsis patients, based on any cut-off in a variable. Subphenotypes are subgroups that can be reliably discriminated from other subgroup based on data-driven assessments. Included studies were randomized controlled trials and cohort studies investigating immunomodulatory therapies in adults with sepsis. Studies were identified by searching PubMed, Embase, Cochrane CENTRAL and ClinicalTrials.gov, from the first paper available until January 29th, 2024. The search resulted in 15,853 studies. Title and abstract screening resulted in 1409 studies (9%), assessed for eligibility; 771 studies were included, of which 282 (37%) were observational and 489 (63%) interventional. Treatment groups included were treatments targeting the innate immune response, the complement system, coagulation and endothelial dysfunction, non-pharmalogical treatment, pleiotropic drugs, immunonutrition, concomitant treatments, Traditional Chinese Medicine, immunostimulatory cytokines and growth factors, intravenous immunoglobulins, mesenchymal stem cells and immune-checkpoint inhibitors. A personalized approach was incorporated in 70 studies (9%). Enrichment was applied using cut-offs in temperature, laboratory, biomarker or genetic variables. Trials often showed conflicting results, possibly due to the lack of patient stratification or the potential influence of severity and timing on immunomodulatory therapy results. When a personalized approach was applied, trends of clinical benefit for several interventions emerged, which hold promise for future clinical trials using personalized immunotherapy. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

14. Transcriptional and functional insights into the host immune response against the emerging fungal pathogen Candida auris

Author

Bruno, Mariolina, Kersten, Simone, Bain, Judith M., Jaeger, Martin, Rosati, Diletta, Kruppa, Michael D., Lowman, Douglas W., Rice, Peter J., Graves, Bridget, Ma, Zuchao, Jiao, Yue Ning, Chowdhary, Anuradha, Renieris, George, van de Veerdonk, Frank L., Kullberg, Bart-Jan, Giamarellos-Bourboulis, Evangelos J., Hoischen, Alexander, Gow, Neil A. R., Brown, Alistair J. P., Meis, Jacques F., Williams, David L., and Netea, Mihai G.

Published
2020
Full Text
View/download PDF

15. Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion

Author

Verweij, Paul E., Rijnders, Bart J. A., Brüggemann, Roger J. M., Azoulay, Elie, Bassetti, Matteo, Blot, Stijn, Calandra, Thierry, Clancy, Cornelius J., Cornely, Oliver A., Chiller, Tom, Depuydt, Pieter, Giacobbe, Daniele Roberto, Janssen, Nico A. F., Kullberg, Bart-Jan, Lagrou, Katrien, Lass-Flörl, Cornelia, Lewis, Russell E., Liu, Peter Wei-Lun, Lortholary, Olivier, Maertens, Johan, Martin-Loeches, Ignacio, Nguyen, M. Hong, Patterson, Thomas F., Rogers, Thomas R., Schouten, Jeroen A., Spriet, Isabel, Vanderbeke, Lore, Wauters, Joost, and van de Veerdonk, Frank L.

Published
2020
Full Text
View/download PDF

18. Incidence and outcome of invasive candidiasis in intensive care units (ICUs) in Europe: results of the EUCANDICU project

Author

Bassetti, Matteo, Giacobbe, Daniele R., Vena, Antonio, Trucchi, Cecilia, Ansaldi, Filippo, Antonelli, Massimo, Adamkova, Vaclava, Alicino, Cristiano, Almyroudi, Maria-Panagiota, Atchade, Enora, Azzini, Anna M., Carannante, Novella, Carnelutti, Alessia, Corcione, Silvia, Cortegiani, Andrea, Dimopoulos, George, Dubler, Simon, García-Garmendia, José L., Girardis, Massimo, Cornely, Oliver A., Ianniruberto, Stefano, Kullberg, Bart Jan, Lagrou, Katrien, Le Bihan, Clement, Luzzati, Roberto, Malbrain, Manu L. N. G., Merelli, Maria, Marques, Ana J., Martin-Loeches, Ignacio, Mesini, Alessio, Paiva, José-Artur, Peghin, Maddalena, Raineri, Santi Maurizio, Rautemaa-Richardson, Riina, Schouten, Jeroen, Brugnaro, Pierluigi, Spapen, Herbert, Tasioudis, Polychronis, Timsit, Jean-François, Tisa, Valentino, Tumbarello, Mario, van den Berg, Charlotte H. S. B., Veber, Benoit, Venditti, Mario, Voiriot, Guillaume, Wauters, Joost, and Montravers, Philippe

Published
2019
Full Text
View/download PDF

19. International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus

Author

Verweij, Paul E., Ananda-Rajah, Michelle, Andes, David, Arendrup, Maiken C., Brüggemann, Roger J., Chowdhary, Anuradha, Cornely, Oliver A., Denning, David W., Groll, Andreas H., Izumikawa, Koichi, Kullberg, Bart Jan, Lagrou, Katrien, Maertens, Johan, Meis, Jacques F., Newton, Pippa, Page, Iain, Seyedmousavi, Seyedmojtaba, Sheppard, Donald C., Viscoli, Claudio, Warris, Adilia, and Donnelly, J. Peter

Published
2015
Full Text
View/download PDF

20. Human TLR10 is an anti-inflammatory pattern-recognition receptor

Author

Oosting, Marije, Cheng, Shih-Chin, Bolscher, Judith M., Vestering-Stenger, Rachel, Plantinga, Theo S., Verschueren, Ineke C., Arts, Peer, Garritsen, Anja, van Eenennaam, Hans, Sturm, Patrick, Kullberg, Bart-Jan, Hoischen, Alexander, Adema, Gosse J., van der Meer, Jos W. M., Netea, Mihai G., and Joosten, Leo A. B.

Published
2014
Full Text
View/download PDF

21. Classical Borrelia Serology Does Not Aid in the Diagnosis of Persistent Symptoms Attributed to Lyme Borreliosis: A Retrospective Cohort Study.

Author

Stelma, Foekje F., Berende, Anneleen, Ter Hofstede, Hadewych, Vrijmoeth, Hedwig D., Vos, Fidel, and Kullberg, Bart-Jan

Subjects
LYME disease, SEROLOGY, BORRELIA, GENERAL practitioners, SERODIAGNOSIS
Abstract

Objective: The diagnosis of Lyme borreliosis is based on two-tier testing using an ELISA and Western blot. About 5–10% of patients report persistent symptoms of unknown etiology after treatment, resulting in substantial difficulties in further diagnostic workup. This paper presents a study aimed at determining whether serology can differentiate between patients with persistent symptoms attributed to Lyme and other patients with Lyme borreliosis. Methods: A retrospective cohort study included 162 samples from four subgroups: patients with persistent symptoms of Lyme (PSL), early Lyme borreliosis with erythema migrans (EM), patients tested in a general practitioner setting (GP), and healthy controls (HC). ELISA, Western blots, and multiplex assays from different manufacturers were used to determine inter-test variations in PSL and to compare reactivity against Borrelia-specific antigens among the groups. Results: In comparing the IgG and IgM reactivity by Western blot, IgG was more often positive in the PSL group than in the GP group. The individual antigen reactivity was similar between the PSL and EM or GP groups. Inter-test agreement among the manufacturers was variable, and agreement was higher for IgG testing compared to IgM. Conclusions: Serological testing is unable to define the subgroup of patients with persistent symptoms attributed to Lyme borreliosis. Additionally, the current two-tier testing protocol shows a large variance among different manufacturers in these patients. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

22. Invasive candidiasis

Author

Pappas, Peter G., Lionakis, Michail S., Arendrup, Maiken Cavling, Ostrosky-Zeichner, Luis, and Kullberg, Bart Jan

Published
2018
Full Text
View/download PDF

24. Serological and Clinical one year follow-up of Patients with Erythema migrans treated in a Romanian Infectious Disease Hospital

Author

Lupșe Mihaela, Briciu Violeta, Flonta Mirela, Nastase Violeta, Todor Nicolae, and Kullberg Bart-Jan

Subjects
lyme disease, erythema migrans, serology, follow up, borreliosis, cheie boala lyme, eritem migrator, serologie, monitorizare, borrelioza, Medicine
Abstract

Eritemul migrator ( EM ) este cea mai comună și recunoscută manifestare clinică precoce a Borreliozei Lyme ( LB ) în Europa. Scop: de a evalua clinic și serologic toți pacienții cu EM și de a corela serologia cu abordarea clinică. Material si metodă: Un studiu prospectiv incluzand toți pacienții care au venit cu EM la Spitalul Clinic de Boli Infecțioase din Cluj - Napoca România între 1 aprilie și 31 august 2011. Am înregistrat date referitoare la: vârstă, sex, intervalul între înțepătura de căpușă și apariția EM, intervalul între apariția EM și prezentarea la spital, serologia (IgM și IgG pentru Borrelia burgdorferi sl) la prezentare și după un an, tratamentul cu antibiotice, durata tratamentului cu antibiotice și evolutia clinică. Rezultate: 44 pacienți cu EM, 2 au avut EM multiplu, 23 bărbați (52 %), cu vârsta medie de 41.3 ani (min 3 ani, maxim 84 ani, in medie 43.5 ani). Serologia la prezentare a fost pozitivă la 15 pacienți pentru IgM și la 9 pacienți pentru IgG cu ELISA și la 13 pentru IgM și la 16 pentru IgG cu WB. După un an de urmărire rezultate pozitive pentru IgM au fost găsite la 14 pacienți cu ELISA și la 11 de pacienți cu WB. IgG a fost pozitivă la 7 pacienți cu ELISA și la 5 cu WB. Intervalul mediu de timp între mușcătura de căpușă și EM nu a fost semnificativ diferit pentru pacienții cu IgM sau IgG negativ sau pozitiv. Intervalul dintre apariția EM și inițierea tratamentului a avut semnificație statistica pentru IgG pozitiv. După un an nu a fost găsită nici o semnificație statistică pentru IgM pozitiv pentru niciunul dintre factorii analizați, în timp ce pentru IgG pozitivitate a fost semnificativ asociată cu vârsta și durata perioadei de incubație. Tratamentul antibiotic si durata acestuia nu au influențat serologia pacienților noastri. Concluzii: Datele noastre aduc dovezi suplimentare că profilul serologic este imprevizibil la pacienții cu Borrelioză Lyme.

Published
2014
Full Text
View/download PDF

28. Toll-like Receptor 1 Polymorphisms Increase Susceptibility to Candidemia

Author

Plantinga, Theo S., Johnson, Melissa D., Scott, William K., van de Vosse, Esther, Edwards, Digna R. Velez, Smith, P. Brian, Alexander, Barbara D., Yang, John C., Kremer, Dennis, Laird, Gregory M., Oosting, Marije, Joosten, Leo A. B., van der Meer, Jos W. M., van Dissel, Jaap T., Walsh, Thomas J., Perfect, John R., Kullberg, Bart Jan, and Netea, Mihai G.

Published
2012
Full Text
View/download PDF

29. Cytokine Gene Polymorphisms and the Outcome of Invasive Candidiasis: A Prospective Cohort Study

Author

Johnson, Melissa D., Plantinga, Theo S., van de Vosse, Esther, Edwards, Digna R. Velez, Smith, P. Brian, Alexander, Barbara D., Yang, John C., Kremer, Dennis, Laird, Gregory M., Oosting, Marije, Joosten, Leo A. B., van der Meer, Jos W. M., van Dissel, Jaap T., Walsh, Thomas J., Perfect, John R., Kullberg, Bart-Jan, Scott, William K., and Netea, Mihai G.

Published
2012
Full Text
View/download PDF

31. Ocular Manifestations of Candidemia

Author

Lashof, Astrid M. L. Oude, Rothova, Aniki, Sobel, Jack D., Ruhnke, Markus, Pappas, Peter G., Viscoli, Claudio, Schlamm, Haran T., Oborska, Iwona T., Rex, John H., and Kullberg, Bart Jan

Published
2011
Full Text
View/download PDF

40. Functional and Genetic Evidence That the Mal/TIRAP Allele Variant 180L Has Been Selected by Providing Protection against Septic Shock

Author

Ferwerda, Bart, Alonso, Santos, Banahan, Kathy, McCall, Matthew B. B., Giamarellos-Bourboulise, Evangelos J., Ramakers, Bart P., Mouktaroudi, Maria, Fain, Pamela R., Izagirre, Neskuts, Syafruddin, Din, Cristea, Tudor, Mockenhaupt, Frank P., Troye-Blomberg, Marita, Kumpf, Oliver, Maiga, Boubacar, Dolo, Amagana, Doumbo, Ogobara, Sundaresan, Santhosh, Bedu-Addo, George, van Crevel, Reinout, Djin-Ye Oh, Lutz Hamann, Schumann, Ralf R., Joosten, Leo A. B., de la Rúa, Concepcion, Sauerwein, Robert, Drenth, Joost P. H., Kullberg, Bart-Jan, van der Ven, André J. A. M., Hill, Adrian V., Pickkers, Peter, van der Meer, Jos W. M., O'Neill, Luke A. J., Netea, Mihai G., and Akira, Shizuo

Published
2009
Full Text
View/download PDF

43. Defining Responses to Therapy and Study Outcomes in Clinical Trials of Invasive Fungal Diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer Consensus Criteria

Author

Segal, Brahm H., Herbrecht, Raoul, Stevens, David A., Ostrosky-Zeichner, Luis, Sobel, Jack, Viscoli, Claudio, Walsh, Thomas J., Maertens, Johan, Patterson, Thomas F., Perfect, John R., Dupont, Bertrand, Wingard, John R., Calandra, Thierry, Kauffman, Carol A., Graybill, John R., Baden, Lindsey R., Pappas, Peter G., Bennett, John E., Kontoyiannis, Dimitrios P., Cordonnier, Catherine, Viviani, Maria Anna, Bille, Jacques, Almyroudis, Nikolaos G., Wheat, L. Joseph, Graninger, Wolfgang, Bow, Eric J., Holland, Steven M., Kullberg, Bart-Jan, Dismukes, William E., and De Pauw, Ben E.

Published
2008
Full Text
View/download PDF

44. Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group

Author

De Pauw, Ben, Walsh, Thomas J., Donnelly, J. Peter, Stevens, David A., Edwards, John E., Calandra, Thierry, Pappas, Peter G., Maertens, Johan, Lortholary, Olivier, Kauffman, Carol A., Denning, David W., Patterson, Thomas F., Maschmeyer, Georg, Bille, Jacques, Dismukes, William E., Herbrecht, Raoul, Hope, William W., Kibbler, Christopher C., Kullberg, Bart Jan, Marr, Kieren A., Muñoz, Patricia, Odds, Frank C., Perfect, John R., Restrepo, Angela, Ruhnke, Markus, Segal, Brahm H., Sobel, Jack D., Sorrell, Tania C., Viscoli, Claudio, Wingard, John R., Zaoutis, Theoklis, and Bennett, John E.

Published
2008
Full Text
View/download PDF

45. Immune Recognition of Candida albicans β-Glucan by Dectin-1

Author

Gow, Neil A. R., Netea, Mihai G., Munro, Carol A., Ferwerda, Gerben, Bates, Steven, Mora-Montes, Héctor M., Walker, Louise, Jansen, Trees, Jacobs, Liesbeth, Tsoni, Vicky, Brown, Gordon D., Odds, Frank C., Van der Meer, Jos W. M., Brown, Alistair J. P., and Kullberg, Bart Jan

Published
2007
Full Text
View/download PDF

46. TLR4 Polymorphisms, Infectious Diseases, and Evolutionary Pressure during Migration of Modern Humans

Author

Ferwerda, Bart, McCall, Matthew B. B., Alonso, Santos, Giamarellos-Bourboulis, Evangelos J., Mouktaroudi, Maria, Izagirre, Neskuts, Syafruddin, Din, Kibiki, Gibson, Cristea, Tudor, Hijmans, Anneke, Hamann, Lutz, Israel, Shoshana, ElGhazali, Gehad, Troye-Blomberg, Marita, Kumpf, Oliver, Maiga, Boubacar, Dolo, Amagana, Doumbo, Ogobara, Hermsen, Cornelus C., Stalenhoef, Anton F. H., van Crevel, Reinout, Brunner, Han G., Oh, Djin-Ye, Schumann, Ralf R., de la Rúa, Concepcion, Sauerwein, Robert, Kullberg, Bart-Jan, van der Ven, André J. A. M., van der Meer, Jos W. M., and Netea, Mihai G.

Published
2007
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results